ABL1 and leukemia: M. Bousquet et al. demonstrated that miR-125b was able to interfere with primary human CD34+ cell differentiation and overexpression of miR-125b is sufficient both to shorten the latency of BCR-ABL-induced leukemia and to independently induce leukemia in a mouse model [39,40].